Management
Dr Deborah Rathjen BSc (Hons), PhD, MAICD
(CEO and Managing Director)
Dr Deborah Rathjen joined Bionomics in June 2000 from Peptech Limited, where she was General Manager of Business Development and Licensing. Dr Rathjen was a co-inventor of Peptech's TNF technology and leader of the company's successful defence of its key TNF patents against a legal challenge by BASF, providing Peptech with a strong commercial basis for licensing negotiations with BASF, Centocor and other companies with anti-TNF products. Dr Rathjen has significant experience in research, business development and licensing. She is an expert in the field of cell biology with specific expertise in inflammation and cancer. Dr Rathjen is currently Chairman of the AusBiotech Board and is a member of the Higher Education Council (SA Government).
Mr Trevor Thiele BA (Accounting), ACA
(Chief Financial Officer and Company Secretary)
Mr Trevor Thiele joins Bionomics after 25 years in various management positions spanning commercial, financial and treasury roles in public listed companies involved in various industries including grain, rural services, retail and food. In these roles Mr Thiele has gained experience in growth companies including mergers, acquisitions and capital raisings. Mr Thiele holds a Bachelor of Arts in Accounting from Uni SA and is a member of the Institute of Chartered Accountants in Australia.
Dr Emile Andriambeloson PhD
(Head of Research Neurofit)
Dr Emile Andriambeloson joined Neurofit in 2002 from Novartis Pharma and has played an important role in the development of Neurofit's business. In 2005 Dr Andriambeloson became the Head of Research at Neurofit and is the key interface with Neurofit's international customer base as well as Bionomics' CNS programs. Dr Andriambeloson has a PhD from the University of Strasbourg in France and is recognised for his expertise in pharmacology. He is the author of 18 articles published in highly regarded peer reviewed scientific journals. Dr Andriambeloson's previous positions include Novartis Pharma (Basel, Switzerland), Heart Research Institute (Sydney, Australia) and University of New South Wales (Sydney, Australia).
Dr Andrew Harvey BSc (Hons) PhD
(Vice President Drug Discovery)
Dr Andrew Harvey joined the chemistry group at Bionomics in 2007 and has led the group in the Multiple Sclerosis collaboration with European pharmaceutical company, Merck Serono, since the collaboration began in June 2008. He played a leading scientific role in the partnering discussions with Merck Serono and has inventorship on each of Bionomics Multiple Sclerosis patents. In 2007, Dr Harvey was instrumental in the establishment of the new chemistry facilities at the Bionomics headquarters in Adelaide. During his prior employment at The Walter and Eliza Hall Institute for Medical Research, Dr Harvey was awarded a National Health and Medical Research Council Industry Fellowship for his research in identifying new treatments for Multiple Sclerosis. He holds a PhD and a BSc (Honours) from Canterbury University in New Zealand.
Dr Gabriel Kremmidiotis BSc (Hons), PhD
(Vice President Research & Development)
Dr Kremmidiotis has a diverse scientific background spanning the fields of Immunology, Molecular Genetics, Bioinformatics, Cancer Biology and Drug Discovery & Development. Dr Kremmidiotis joined Bionomics in January 2002. His early work at Bionomics was primarily focused on Cancer Biology. More recently, his role has expanded to the management of all Bionomics drug discovery and development programs. Dr Kremmidiotis has published research findings in 23 international scientific publications and has several patent inventions on cancer genes and small molecule anti-cancer therapeutics. Dr Kremmidiotis is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.
